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Patent foramen ovale (PFO) is associated with cryp-togenic stroke (CS).1 Despite this association, there 
is continued debate about the causal relationship of dis-
covered PFOs in patients with CS.2,3 Numerous candidate 
echocardiographic features have been proposed as high-risk 
features that make a PFO more likely to be causally linked 
to CS, including presence of a hypermobile atrial septum 
(or atrial septal aneurysm [ASA]),4 physiologic shunt size 
as measured by right-to-left microbubble count,5 and pres-
ence of a right-to-left shunt at rest (ie, without a Valsalva 
maneuver).6 Investigators have incorporated these potential 
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high-risk parameters into routine echocardiographic analysis 
in an attempt to identify high-risk PFOs from incidentally 
discovered ones. Nevertheless, reports raise the possibility 
that these echocardiographic features are not clearly related 
to either CS or the risk of recurrence.3,7,8 This uncertainty 
adds to the debate about causality and raises questions about 
appropriate therapeutic approaches.9
We report an analysis from the Risk of Paradoxical 
Embolism (RoPE) database,10 a large observational database 
formed by combining 12 component databases of patients 
with CS and known PFO status. The rationale for the RoPE 
study has been previously described and builds on previous 
work demonstrating that overall summary trial results may not 
represent beneﬁts for individual patients and that risk mod-
eling may improve result interpretation.11,12 These issues are 
important for trial design and for treating patients because the 
likelihood that a CS event is attributable to an identiﬁed PFO 
is related to patient-speciﬁc factors, and PFO closure may not 
be beneﬁcial for all patients with CS and PFO.13,14
The RoPE score is a way to stratify patients with CS with 
respect to the (1) likelihood that a PFO would be present 
(before transesophageal echocardiography [TEE] evalua-
tion), and (2) (related) probability that CS is attributable to 
an observed PFO.15 In brief, among patients with PFO and 
CS, younger patients, without conventional stroke risk fac-
tors or previous stroke and with a visible superﬁcial lesion 
seen on neuroimaging, seem to be more likely to have a 
PFO-attributable CS. Using the RoPE score, we attempted 
to clarify the clinical signiﬁcance of the major high-risk PFO 
echocardiographic features. Our hypothesis is that high-risk 
echocardiographic features will be more prevalent in patients 
with probable PFO-associated CS and less prevalent in those 
with probable incidental PFOs.
Methods
The RoPE database has been described previously.10,16 Brieﬂy, we 
combined 12 databases containing clinical, neuroimaging, and echo-
cardiographic data of patients with CS who were investigated for 
PFO. The RoPE study includes patients with (n=1925) and with-
out (n=1749) PFO (see Figure).17–22 CS was deﬁned by the Trial of 
Org 10172 in Acute Stroke Treatment (TOAST) classiﬁcation and 
was diagnosed within component databases.23 As previously de-
scribed,16 CS deﬁnition for this study speciﬁcally excluded patients 
with known stroke mechanisms, such as large artery atherosclerosis, 
cardioembolism, small vessel disease, or strokes of other causes, 
including arterial dissection or hypercoagulable states. Stroke was 
deﬁned as the sudden onset of neurological deﬁcit in a vascular ter-
ritory, presumed to be due to focal ischemia after a comprehensive 
workup. If a deﬁcit was present for <24 hours, it was considered a 
transient ischemic attack if there were no acute magnetic resonance 
imaging or computed tomography changes in appropriate locations. 
Patients underwent either TEE or transcranial Doppler for PFO de-
tection. For this analysis, only patients evaluated with TEE (n=1324) 
were included. Component database variables were harmonized, and 
new data were collected when necessary and feasible. This study was 
approved by the Tufts Medical Center Internal Review Board.
The RoPE score is a prediction tool for determining the probability 
that an index CS is attributable to PFO (Table 1). For an individual, 
it may not be possible to identify with certainty whether a PFO is 
incidental or pathogenic. The 10-point RoPE score allows estimation 
of the attributable fraction for a PFO in the setting of CS. Attributable 
fraction is determined by the prevalence of PFO in patients with CS 
compared with that found in an otherwise similar group of patients 
without CS. Because PFO prevalence in CS patients is dependent 
on other patient characteristics,24 a more patient-speciﬁc attributable 
Figure.  Cases included in transesophageal echocardiography analysis.
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fraction can be considered by applying a patient-speciﬁc PFO prev-
alence rate.15 Generally, with a decreasing number of conventional 
stroke risk factors and younger age (resulting in a higher RoPE score 
and an increasing PFO prevalence), the PFO-attributable fraction 
(which, assuming causality, can be thought of as the proportion of 
strokes that would not have occurred if PFO had been previously 
eliminated) increases.
For this analysis, individual RoPE scores were calculated for each 
of the 1324 cases with PFO investigated by TEE. Echocardiographic 
variables were harmonized values based on clinical rationale and pri-
mary data from the component databases (published or unpublished). 
RoPE study investigators, through e-mail, telephone, teleconference, 
and face-to-face meetings, came to consensus regarding how to har-
monize the echocardiographic parameters.16 Hypermobility of the 
interatrial septum (yes/no) was deﬁned as maximum septal excur-
sion from the midline into the right or left atrium (Bern published,25 
Patent Foramen Ovale in Cryptogenic Stroke Study [PICSS] Study,8 
German,19 Lausanne, Tufts,21 Aortic Plaque and Risk of Ischemic 
Stroke [APRIS] Study,26 French PFO/ASA27) and total excursion be-
tween right and left atria (Recurrent Stroke and Massive Right-to-Left 
Shunt [CODICIA] Study).18 The consensus deﬁnition of hypermobility 
in our database refers to ≥10 mm of excursion from midline and is ap-
proximately equivalent to ASA used in the literature. Shunting across 
the PFO at rest (yes/no) was considered present if right-to-left shunting 
of bubbles was observed even in the absence of a Valsalva maneuver. 
All centers were likely to inject microbubbles from the upper extrem-
ity. Physiologic shunt size (large/small) was based on counting bub-
bles in the left atrium ≤3 cardiac cycles after right atrial opaciﬁcation. 
Microbubbles observed after 3 cardiac cycles were not used to assess 
shunt severity. Large shunt size was deﬁned differently in component 
databases: >10 bubbles (APRIS,26 Bern published,25 CODICIA,18 
Lausanne, and PICSS8), ≥10 bubbles (French PFO/ASA,27 German19), 
and >15 bubbles (Tufts21). The consensus deﬁnition of large shunt size 
was deﬁned in our database as >10 bubbles in the left atrium ≤3 car-
diac cycles after right atrial opaciﬁcation.16 Our hypothesis is that these 
echocardiographic features will be more frequently observed in RoPE 
score strata with a higher probability of PFO-attributable stroke.
Statistical Analysis
For our primary analysis, we divided the population into those with 
a RoPE score that was above or below the median, that is, those with 
scores >6 (higher probability of PFO-attributable stroke) and <6 (lower 
probability of PFO-attributable stroke). Signiﬁcance was determined 
using t-test and χ2 analyses with signiﬁcance set at P=0.05. We used a 
generalized linear mixed model that included a random-effect term rep-
resenting each component database when determining the signiﬁcance 
of the various echocardiographic ﬁndings across RoPE score catego-
ries. For these analyses, the independent variable was the RoPE score; 
the dependent variable was presence or absence of putative high-risk 
TEE features. Our secondary analysis consisted of a test of linear trend 
with >7 ordered RoPE score categories, again using generalized mixed 
models where the study site was included as a random effect. We also 
performed extensive sensitivity analyses that evaluated association be-
tween RoPE score categories and composite PFO risk proﬁles: (1) large 
size and hypermobile septum, (2) not large and not hypermobile, and 
(3) large size or hypermobile. We evaluated the inter-reader reliability 
(κ) for the proposed high-risk TEE features by having 3 blinded read-
ers reread a sampling of studies from the French PFO/ASA and PICSS 
studies. In addition, we explored for association by redeﬁning large 
shunt size using a higher uncountable number of bubbles.
Results
The characteristics of subjects included in this analysis are 
shown in Table 2. There were 1294 subjects with CS and 
PFO and TEE data (see Figure). The mean age was 50 years; 
59% of patients were white. There were 637 subjects with 
RoPE score >6 and 657 with RoPE score ≤6. This stratiﬁca-
tion produced subgroups with different characteristics: those 
in the low RoPE score group were 10-fold more likely to 
have diabetes mellitus, 5-fold more likely to have coronary 
artery disease, and ≈8-fold more likely to have hypertension 
(P<0.0001 for age, presence of diabetes mellitus, coronary 
artery disease, hypertension, hypercholesterolemia, and his-
tory of stroke or transient ischemic attack; P=0.03 for cur-
rent smoking).
The proposed high-risk PFO characteristics seen on TEE 
were commonly seen in the RoPE database (Table 3). A 
sampling of TEE studies was reread by 3 readers to estab-
lish inter-reader reliability within the RoPE database. For 29 
TEE studies from the French PFO/ASA study, κ=0.57 for 
hypermobile septum, 0.42 for large PFO, and 0.75 for shunt 
at rest, and for 31 TEE studies from the PICSS study, κ=0.33 
for hypermobile septum, 0.14 for large PFO, and 0.33 for 
shunt at rest. Inter-reader agreement for these variables was 
consistent with previously published standards.28 Overall, 
25.3% had a hypermobile septum, 64.4% had a large shunt, 
and 69.6% had a shunt at rest. However, there was no dif-
ference in the frequency of these echocardiographic PFO 
features between the high RoPE score (higher probability of 
PFO-related index stroke) and low RoPE score (lower prob-
ability of PFO-related index stroke) cohorts (odds ratio [OR], 
0.92; P=0.53 for large number of bubbles; OR, 1.15; P=0.45 
for right-to-left shunt at rest; OR, 0.80; P=0.11 for presence 
of a hypermobile septum). Extensive exploratory analyses of 
echocardiographic features across RoPE score strata demon-
strated no trend toward increased frequency as RoPE score 
increased after correcting for site effect. The prevalence of 
these TEE features varied across different centers for any 
given RoPE score stratum (see the Data Supplement I). 
Furthermore, we saw no trends after exploring different deﬁ-
nitions of large shunt size and no association between RoPE 
score category and composite PFO risk proﬁles (see the Data 
Supplement II).
Table 1. RoPE Score Calculator
Characteristic Points RoPE Score
No history of hypertension 1
No history of diabetes mellitus 1
No history of stroke or TIA 1
Nonsmoker 1
Cortical infarct on imaging 1
Age, y
  18–29 5
  30–39 4
  40–49 3
  50–59 2
  60–69 1
  ≥70 0
Total score (sum of individual points)
  Maximum score (a patient <30 y with no hypertension, no 
diabetes mellitus, no history of stroke or TIA, nonsmoker, and 
cortical infarct)
10
  Minimum score (a patient ≥70 y with hypertension, diabetes 
mellitus, previous stroke, current smoker, and no cortical infarct)
0
RoPE indicates Risk of Paradoxical Embolism; and TIA, transient ischemic attack. 
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Discussion
Because treatment decisions may rely on whether a discovered 
PFO is pathogenically related to the index stroke, it is criti-
cally important to identify reliable ways to stratify the likeli-
hood that an identiﬁed PFO is associated with stroke. Although 
some proposed high-risk TEE features have been reported to 
be associated with CS in previous case–control studies, these 
previous studies report on a small number of patients and are 
often not statistically signiﬁcant.8,29–37 Moreover, recognized 
potential high-risk features, including a persistent Eustachian 
valve, are not consistently reported in the literature.38 This 
analysis from the RoPE study demonstrates that previously 
proposed high-risk TEE ﬁndings of septal hypermobility, shunt 
at rest, and physiologically large shunt do not seem to be more 
frequently found in patients whose clinical and neuroimaging 
features (ie, superﬁcially located lesions) are highly suggestive 
of a PFO-attributable index stroke.
The null results from our study can be interpreted in sev-
eral ways. First, the so-called high-risk PFO features may play 
no etiologic role in stroke; although the association between 
PFO and CS is presumed to be due to paradoxical embolism, 
there may be other important mechanisms unrelated to shunt-
ing or septal hypermobility. Second, although the features 
may, in fact, lead to higher risk of stroke (through paradoxical 
embolism or other mechanisms), their ascertainment by TEE 
is imperfect and highly variable. Even when examining the 
same studies, inter-reader agreement would be surprisingly 
low, and (as discussed below) the studies are highly depen-
dent on techniques and on patient factors that vary over time. 
Extensive exploratory analyses failed to identify trends when 
evaluating data from individual sites with uniform proto-
cols (see the Data Supplement I). Third, in this study, TEE 
variables were collected at multiple sites under independent 
research protocols. These pragmatic conditions may have fur-
ther increased measurement error. Fourth, although the rela-
tionship between the RoPE score and the presence of PFO was 
robust in this database, it is not possible to segregate patients 
for whom PFO is and is not causally related to their stroke. 
Finally, it is possible that the PFO association is mediated by 
different mechanisms, of which some depend on a large shunt, 
for example, paradoxical embolism, whereas others depend 
on a small shunt, for example, in situ thrombus formation. As 
previously reported, assuming a control PFO prevalence rate 
of 25%, the PFO-attributable fraction for patients with CS 
ranged from 0% (95% conﬁdence interval [CI], 0%–4%) for 
patients with RoPE score 0 to 3, to 88% (95% CI, 83%–91%) 
for patients with RoPE score 9 to 10.15 Because patients with 
and without a true association between CS and PFO were 
Table 3. Putative High-Risk TEE Features Across High and Low RoPE Score Strata
TEE Findings
All PFO Patients 
With At Least Some 
TEE Data (n=1294)
RoPE Score >6 
(n=637)
RoPE Score ≤6 
(n=657) P Value*
Large no. of bubbles vs not large 64.4% (695/1079) 67.4% (347/515) 61.7% (348/564) 0.5286
Shunt at rest vs no shunt 69.6% (484/695) 67.6% (238/352) 71.7% (246/343) 0.4474
Hypermobile septum vs not 25.3% (320/1265) 23.0% (144/626) 27.5% (176/639) 0.1063
PFO indicates patent foramen ovale; RoPE, Risk of Paradoxical Embolism; and TEE, transesophageal echocardiography.
*P values from generalized mixed models (TEE variables only) after adjusting for random site effect.
Table 2. Patient Characteristics Across RoPE Score Strata 
All PFO Patients With At 
Least Some TEE Data
(n=1294) RoPE Score >6 (n=637) RoPE Score ≤6 (n=657) P Value*
Patient characteristics
  Age, y, mean±SD 49.6±14.6 (1294) 38.9±9.2 (637) 60.0±10.8 (657)
  Age >65 y 17.9% (232/1294) 0.0% (0/637) 35.3% (232/657)
  Men 59.4% (768/1294) 54.6% (348/637) 63.9% (420/657) 0.0007
  White race 86.6% (453/523) 93.4% (283/303) 77.3% (170/220) <0.0001
  Incident event was TIA 14.0% (181/1294) 9.7% (62/637) 18.1% (119/657) <0.0001
Medical history, % yes
  Diabetes mellitus 8.7% (112/1289) 1.3% (8/636) 15.9% (104/653)
  Coronary artery disease 7.1% (63/885) 2.0% (7/343) 10.3% (56/542) <0.0001
  Hypertension 29.2% (377/1290) 6.0% (38/637) 51.9% (339/653)
  Hypercholesterolemia 24.2% (242/998) 12.1% (62/512) 37.0% (180/486) <0.0001
  Current smoker 29.6% (380/1282) 26.9% (171/636) 32.4% (209/646)
  History of stroke or TIA 11.9% (154/1290) 5.0% (32/635) 18.6% (122/655)
Patient-level data were extracted from individual databases. Age represents the age at the time of index event. PFO 
indicates patent foramen ovale; RoPE, Risk of Paradoxical Embolism; TIA, transient ischemic attack; and TEE, transesophageal 
echocardiography.
*P-values from t-test (age), or χ2 test.
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included in both comparison groups, the potential effect of the 
high-risk features may have been underestimated.
Although it is likely that each of these sources contributed to 
our null ﬁndings, the inability of TEE to robustly identify high-
risk PFOs is a concern because TEE remains the gold standard 
by which anatomic characteristics of PFOs are characterized. 
Speciﬁc TEE protocols are not standardized across institutions, 
instantaneous loading conditions may ﬂuctuate, and anatomic 
and functional features are variably reported in the literature.39
ASA is characterized by a saccular formation of the inter-
atrial septum that may protrude into either atrium. The term 
itself represents a spectrum of atrial septal morphological 
changes.40 It is variably deﬁned in the literature as septal move-
ment of >10 or >15 mm.8,41 The causal relationship between 
ASA and CS has not been ﬁrmly established, although hypoth-
eses include embolization of thrombi formed within the ASA, 
thrombus formation secondary to subclinical atrial arrhyth-
mias, and alterations of septal movement that promote right-left 
shunting.27 Recently reported exploratory analyses suggest that 
those with ASA present beneﬁt from device closure compared 
with those without this septal anatomy, although this was not 
seen consistently.14,42 Interestingly, as reported in the literature, 
there is signiﬁcant inter-and intraobserver variability in detect-
ing this abnormality (even in research settings), likely limiting 
the discriminatory ability of this ﬁnding.28 Morphological het-
erogeneity, varying deﬁnitions, and inconsistent detection may 
all contribute to the explanation as to why our analysis showed 
no clear relationship with RoPE strata in the RoPE database.
Our analysis evaluated microbubble count, 1 of the most 
commonly used tools for semiquantitative characterization of 
shunt size. Inconsistency of ﬁne gradations of microbubble 
count is likely because these counts are made based on a sin-
gle frame in a single imaging plane and, thus, may not repre-
sent the actual amount of shunting.43 Moreover, the number of 
microbubbles does not correlate well with the anatomic size of 
a PFO.44 Quantiﬁcation of PFO size can be determined by the 
separation between septum primum and septum secundum in 
the bicaval view both at rest and during Valsalva maneuver.45 
This view, which is possible for most medium- and large-
sized PFOs, was not consistently performed across the com-
ponent RoPE databases. A further limitation of microbubble 
count, as determined in this study, is that important variation 
in shunt size may occur well beyond our cut-off value of 10. 
Although we also saw no effect using higher cut-offs, tech-
nical limitations of TEE may prevent measuring shunt size 
when the bubbles are uncountable, although variation in this 
range may be clinically signiﬁcant. Newer methods of shunt 
detection may offer an increased ability to quantify the shunt 
objectively and over a wider range.46 The measured shunt 
size may also differ depending on whether microbubbles are 
injected from the upper (as is standard) or the lower extremi-
ties (perhaps better reﬂecting the presumed mechanism due 
to lower extremity or pelvic vein thrombi). In part because 
shunting from the lower extremity may depend on the pres-
ence and characteristics of a Eustachian valve (unmeasured 
across most RoPE component studies), measures of shunting 
from these 2 sources may be poorly correlated.45,47 A minority 
of included databases (Bern and PICSS) systematically ascer-
tained information on the Eustachian valve.47 As a result, this 
feature was not included in our analysis. These limitations, in 
association with signiﬁcant inter-reader variability in bubble 
count, create noise that may contribute to the null result for 
this variable.27,28
Similarly, the presence of a right-to-left shunt at rest is 
highly variable and dependent on technique and loading 
conditions. Physiological pressure differences between the 
right and left atria usually push the septum primum against 
the septum secundum. Momentary changes in pressures 
can result in a transient elevation of right atrial pressure so 
that it is greater than left atrial pressure. The free edge of 
the septum primum may move, resulting in enlargement of 
the PFO oriﬁce.9 Transient shunting and directional shift 
can be seen in the setting of changes in volume status or 
body positioning. An effective Valsalva maneuver, deﬁned 
by complete bowing of the interatrial septum toward the 
left atrium, may be difﬁcult when sedation is too heavy.39 
Moreover, this hemodynamic state represents 1 of many cir-
cumstances where right atrial pressure may rise above that 
seen in the left atrium. Because the presence of right-to-left 
shunting is critically dependent on instantaneous interatrial 
pressure differences, it is not surprising that this short-term 
observation as documented in the component RoPE data-
base studies is an unreliable marker of long-term paradoxi-
cal embolism risk.
In summary, we found no evidence that subjects with CS 
and clinical features suggestive of PFO-attributable stroke 
are more likely to have putative high-risk TEE features than 
those whose clinical features suggest CS unrelated to their 
PFO. Because of numerous technical limitations, TEE may 
be unreliable in risk-stratifying PFO on the basis of physi-
ological and anatomic features. Although some of the limi-
tations discussed here relate to limitations in how TEE was 
applied in the component RoPE studies and may be partially 
addressable through more rigorous standardization of imag-
ing procedures, our results can also be seen as reﬂecting the 
limitations of TEE measurements as they are usually per-
formed in routine clinical practice. Further development of 
technologies that might better and more consistently charac-
terize PFO features is needed.
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CLINICAL PERSPECTIVE
Patent foramen ovale (PFO) is associated with cryptogenic stroke (CS), although the pathogenicity of an observed PFO 
for an individual is unknown. Transesophageal echocardiography (TEE) features such as PFO size, hypermobile septum 
(atrial septal aneurysm), and presence of a right-to-left shunt at rest are proposed high-risk features. The Risk of Paradoxical 
Embolism (RoPE) database, evaluated here, is a large observational database formed by combining 12 component databases 
of patients with CS and known PFO status. We used the RoPE score, a recently developed score based on clinical data and 
neuroimaging, to stratify patients with PFO and CS by the probability that CS is attributable to an observed PFO. We evalu-
ated whether high-risk TEE features were seen more frequently in patients more likely to have a PFO-associated stroke. 
This analysis shows no association between purported high-risk TEE features and the likelihood that an observed PFO is 
pathogenically related to CS. Additional tools to describe PFOs may be helpful in determining whether an observed PFO is 
incidental or likely pathogenically related to CS.
